Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Lundbeck Offering A Lot Of 'Ifs' And Potential

If everything works out, H. Lundbeck A/S (OTCPK:HLUYY) is going to be one of the best European mid-cap drug stocks over the next couple of years. If a few key programs fail to work out, though, it's going to be hard to justify even today's price, let alone a higher one. That puts Lundbeck squarely into an investing grey zone, as the risk and reward are much higher than for a typical pharmaceutical company, but quite a bit less than for a true biotech.

I continue to be bullish on the company's outlook and prospects. Lundbeck is a CNS specialist, and one that has been clearly trying to learn from industry experience in depression, Alzheimer's, schizophrenia, and other...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details